The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
“…We have a tonne of intrinsic inherent value right now in our Pilot Mountain project…”
Full Article link :
https://total-market-solutions.com/2024/05/golden-metal-resources-plc-may-2024/
Interview only link :
https://youtu.be/pPmh6ZBnppM
“…data has been called the new oil. This is the new oil. We will strike a lot of oil…”
https://total-market-solutions.com/2024/05/electric-guitar-plc-may-2024/
Https://ukinvestormagazine.co.uk/poolbeg-pharma-shares-jump-after-announcing-year-of-progress/
Interview -
“…Our aim is to, hopefully have already potentially possibly invested in some of the winners that are coming in the next few years…”
https://total-market-solutions.com/2024/05/coinsilium-may-2024/
Ummmmm…
Looks like #HMI back on track with the fertiliser and the REE could be the huge cherry on top for @harvestminerals 🍒
“…Despite the ongoing tightness in market prospects, there are signs of improvement in the second half of the year…”
https://www.londonstockexchange.com/news-article/HMI/kp-fertil-r-sales-update/16452782
Https://www.blockenergy.co.uk/wp-content/uploads/2024/05/block_energy_factsheet_may_24.pdf
Https://twitter.com/PoolbegPharma/status/1785928353549001126
The future has never been brighter for Bluejay
“…A project with this size and scale will attract the attention of the majors, of which we know at least one is particularly interested…”
https://total-market-solutions.com/2024/05/bluejay-mining-plc-may-2024/
They received the fully granted patent from the US Patent Office for our Immunomodulator II patent application.
The claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indication
https://www.londonstockexchange.com/news-article/POLB/significant-polb-001-patent-granted-in-usa/16448784
NO OFFERS. BID for millions. Ready for next move back to 4p?
"...Separately, I am delighted to share that we have secured an exclusive 12-month option agreement with Silk Road Therapeutics to acquire an orphan drug candidate, a novel topical muco-adherent formulation of Pentoxifylline (PTX) for the treatment of oral ulcers in patients suffering from Behçet's Disease for a nominal fee. The foundation of any pharma company is a strong pipeline of assets, and we believe that topical PTX could fit well into our pipeline alongside our other assets as we increase our focus on rare and orphan diseases. Under this option agreement, we will advance our due diligence process and engage with Silk Road Therapeutics to further understand the clinical pathway to approval..."
https://www.londonstockexchange.com/news-article/POLB/option-agreement-to-acquire-orphan-drug-candidate/16446501
"...Finaly, we announced the appointment of Shore Capital as our Joint Broker, with Cavendish remaining as Nomad alongside Davy as our other Joint Broker. Shore Capital acted as Nominated Adviser and Joint Broker to Amryt Pharma plc during its listing on AIM in 2016, its strategic acquisitions and its dual listing on Nasdaq, and as such, they bring valuable expertise to Poolbeg Pharma as we seek to repeat the success of Amryt Pharma. With a proven track record of working with companies in the rare and orphan disease space, Shore Capital is well positioned to support Poolbeg as it pursues a similar strategic growth trajectory to Amryt...."
https://www.londonstockexchange.com/news-article/POLB/appointment-of-joint-broker/16446562
Full year results for the year ended 31 December 2023. Clearly their disciplined approach to capital allocation has ensured that they have have maintained a robust cash position of £12.2m at year end.
https://www.londonstockexchange.com/news-article/POLB/results-for-the-year-ended-31-december-2023/16446315
Poolbeg Pharma has announced FY 2023 results to end December 2023, which positively reflect the company’s capital-efficient operating model with net cash of £12.2m being reported, significantly ahead of our expectations (2023E: £10.9m). Meaningful R&D progress whilst maintaining financial prudence means that Poolbeg enters 2024 with a strong balance sheet in absolute terms and relative to many biotech peers, with a cash runway (to fund the existing R&D pipeline) we forecast will extend into 2026. This runway could be further extended should future revenues from potential partnering or licensing deals materialise. In our view, the data package for Poolbeg’s lead pipeline asset, POLB 001, has been significantly strengthened in 2023 and with the strategic expansion of the drug into oncology we believe POLB 001 could be viewed as an attractive licensing opportunity in the eyes of potential partners.
POLB CEO is joined by the CEO of Silk Road Therapeutics on @Proactive_UK:
🤝 Silk Road Therapeutics option agreement
🦠 Behçet's Disease
🔬 Development of tPTX
🧲 Commercial Attraction
👁️ Overview of #POLB full year results
https://www.youtube.com/watch?v=MOTQwbvmIuQ&t
European Green Transition (AIM:EGT) has signed an exclusive option agreement to acquire a copper tailings recycling project at Limni in Cyprus.
The Limni Project perfectly fits their aim to pursue what they believe are high quality opportunities where they can potentially generate near term cash flow efficiently. They have seen a strong interest in copper with increased M&A activity, particularly in the London market. In light of shortages and rising prices for the metal, they believe this project is well placed to benefit from Europe’s green energy transition.
In addition to the copper tailings recycling project, there looks an excellent opportunity to develop a second revenue stream at the site by developing a solar power facility there. Around 80% of Cyprus’ energy supply is currently based on fossil fuels, providing an opening to develop and operate a domestic, renewable energy source, and with the high level of solar radiation across Cyprus, a solar project is a perfect fit. It is EGT’s intention that the funding of any such facility would be funded entirely by an existing solar power provider with the potential for EGT to receive an annual long-term revenue stream from the solar power operator.
This is very exciting news for EGT, and it is an example of the company’s strategy in action, broadening focus and expanding their scope to access green economy projects in Europe. The Limni Project perfectly fits their aim to pursue what they believe are high quality opportunities where they can potentially generate near term cash flow efficiently, while also prioritising the environment and the local community.